Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Eiger BioPharmaceuticals stock

EIGR
US28249U1051
A2AF9X

Price

8.50
Today +/-
+0
Today %
+0 %
P

Eiger BioPharmaceuticals Revenue, EBIT, Net Income

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eiger BioPharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eiger BioPharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eiger BioPharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eiger BioPharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eiger BioPharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eiger BioPharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eiger BioPharmaceuticals’s growth potential.

Eiger BioPharmaceuticals Revenue, EBIT and net profit per share

DateEiger BioPharmaceuticals RevenueEiger BioPharmaceuticals EBITEiger BioPharmaceuticals Net Income

Eiger BioPharmaceuticals stock margins

The Eiger BioPharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eiger BioPharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eiger BioPharmaceuticals.

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eiger BioPharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Eiger BioPharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eiger BioPharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eiger BioPharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eiger BioPharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eiger BioPharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eiger BioPharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eiger BioPharmaceuticals Margin History

Eiger BioPharmaceuticals Gross marginEiger BioPharmaceuticals Profit marginEiger BioPharmaceuticals EBIT marginEiger BioPharmaceuticals Profit margin

Eiger BioPharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Eiger BioPharmaceuticals earnings per share therefore indicates how much revenue Eiger BioPharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eiger BioPharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eiger BioPharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eiger BioPharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eiger BioPharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eiger BioPharmaceuticals Revenue, EBIT and net profit per share

DateEiger BioPharmaceuticals Sales per ShareEiger BioPharmaceuticals EBIT per shareEiger BioPharmaceuticals Earnings per Share

Eiger BioPharmaceuticals business model

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals is one of the most popular companies on Eulerpool.com.

Eiger BioPharmaceuticals SWOT Analysis

Strengths

Eiger BioPharmaceuticals Inc has several key strengths that contribute to its success:

  • Strong product pipeline with innovative and promising drugs
  • Robust research and development capabilities
  • Experienced and knowledgeable management team
  • Strong partnerships with reputable pharmaceutical companies
  • Solid financial position

Weaknesses

Despite its strengths, Eiger BioPharmaceuticals Inc also faces certain weaknesses:

  • Relatively small market presence compared to established competitors
  • Limited marketing and distribution capabilities
  • Dependence on a few key drugs in its portfolio
  • Vulnerability to regulatory changes and approvals

Opportunities

Eiger BioPharmaceuticals Inc can leverage the following opportunities to further grow:

  • Expanding market for its targeted therapies
  • Increasing demand for innovative and effective drugs
  • Collaborations and partnerships for research and development
  • Access to funding for further expansion

Threats

Eiger BioPharmaceuticals Inc faces the following threats that may impact its business:

  • Intense competition from larger and well-established pharmaceutical companies
  • Stringent regulatory requirements and approval processes
  • Economic uncertainties and market fluctuations
  • Emerging technologies and alternative treatment options

Eiger BioPharmaceuticals Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eiger BioPharmaceuticals Revenue by Segment

Segmente2023
Product revenue, net15.52 M USD
Other revenue250,000 USD

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eiger BioPharmaceuticals Revenue by Segment

Segmente2023
Autorisation Temporaire D Utlisation Member2.4 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Eiger BioPharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Eiger BioPharmaceuticals stock splits

In Eiger BioPharmaceuticals's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-9.9 -12.3  (-24.19 %)2023 Q3
6/30/2023-12.55 -14.1  (-12.39 %)2023 Q2
3/31/2023-14.47 -15.6  (-7.78 %)2023 Q1
12/31/2022-16.63 -17.1  (-2.8 %)2022 Q4
9/30/2022-0.53 -0.62  (-16.59 %)2022 Q3
6/30/2022-0.62 -0.51  (17.56 %)2022 Q2
3/31/2022-0.66 -0.64  (2.45 %)2022 Q1
12/31/2021-0.65 -0.64  (1.93 %)2021 Q4
9/30/2021-0.57 -0.65  (-13.6 %)2021 Q3
6/30/2021-0.56 -0.57  (-2.13 %)2021 Q2
1
2
3
4

Most common questions regarding Eiger BioPharmaceuticals

What values and corporate philosophy does Eiger BioPharmaceuticals represent?

Eiger BioPharmaceuticals Inc represents innovation, dedication, and excellence in the biopharmaceutical industry. Founded on the principle of advancing novel therapies for rare and ultra-rare diseases, Eiger BioPharmaceuticals Inc is committed to improving patients' lives by developing cutting-edge treatments. The company's corporate philosophy revolves around scientific rigor, collaboration, and patient-centered focus. Eiger BioPharmaceuticals Inc's unwavering commitment to scientific integrity and breakthrough innovations drives their mission to bring transformative medicines to patients globally. With a focus on meeting unmet medical needs, Eiger BioPharmaceuticals Inc continues to push boundaries in drug development, making it a leader in the biopharmaceutical sector.

In which countries and regions is Eiger BioPharmaceuticals primarily present?

Eiger BioPharmaceuticals Inc primarily operates in the United States. The company is based in Palo Alto, California and focuses on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. With a strong presence in the U.S. healthcare sector, Eiger BioPharmaceuticals Inc operates within the dynamic and innovative biotechnology industry. Their dedication to finding solutions for unmet medical needs has positioned them as a prominent player in the U.S. market.

What significant milestones has the company Eiger BioPharmaceuticals achieved?

Eiger BioPharmaceuticals Inc has achieved several significant milestones. The company successfully completed a Phase 2 ULTRA clinical study for Lonafarnib in Hepatitis Delta Virus (HDV) infection, demonstrating positive results. Furthermore, Eiger initiated Phase 3 D-LIVR study evaluating Lonafarnib in HDV patients, displaying its commitment to advanced treatments. Additionally, the company received Breakthrough Therapy Designation from the FDA for its drug Avexitide in Post-Bariatric Hypoglycemia, acknowledging its potential to fill an unmet medical need. Eiger BioPharmaceuticals Inc continues to make strides in developing innovative therapies and improving patient outcomes in various disease areas.

What is the history and background of the company Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals Inc is a pharmaceutical company specializing in the development of targeted therapies for rare diseases. Founded in 2008, the company is headquartered in Palo Alto, California. Eiger BioPharmaceuticals focuses on developing innovative treatments for diseases such as Hepatitis Delta Virus (HDV) infection, which currently has no approved therapies. With a dedicated team of scientists and researchers, Eiger BioPharmaceuticals has made significant progress in advancing potential breakthrough treatments and has successfully conducted various clinical trials. The company's commitment to addressing unmet medical needs and their expertise in rare diseases make them a key player in the biopharmaceutical industry.

Who are the main competitors of Eiger BioPharmaceuticals in the market?

The main competitors of Eiger BioPharmaceuticals Inc in the market are companies like Gilead Sciences, Vertex Pharmaceuticals, and Intercept Pharmaceuticals.

In which industries is Eiger BioPharmaceuticals primarily active?

Eiger BioPharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals Inc's business model focuses on developing and commercializing innovative therapies for rare and ultra-rare diseases. The company aims to address unmet medical needs and improve the lives of patients with limited treatment options. Eiger BioPharmaceuticals primarily focuses on developing targeted therapies that modulate the underlying disease pathways, aiming to provide safe and effective treatment options. With a strong emphasis on research and development, the company collaborates with leading academic institutions and partners to advance its pipeline of potential therapies. By leveraging its expertise in drug discovery and development, Eiger BioPharmaceuticals aims to bring novel treatments to market and make a positive impact in the healthcare industry.

What is the P/E ratio of Eiger BioPharmaceuticals 2024?

The P/E ratio cannot be calculated for Eiger BioPharmaceuticals at the moment.

What is the P/S ratio of Eiger BioPharmaceuticals 2024?

The P/S cannot be calculated for Eiger BioPharmaceuticals currently.

What is the Quality Investing of Eiger BioPharmaceuticals?

The Quality Investing cannot be calculated for Eiger BioPharmaceuticals at the moment.

What is the revenue of Eiger BioPharmaceuticals 2024?

The revenue cannot currently be calculated for Eiger BioPharmaceuticals.

How high is the profit of Eiger BioPharmaceuticals 2024?

The profit cannot currently be calculated for Eiger BioPharmaceuticals.

What is the business model of Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Inc is a biotechnology company focused on the development and commercialization of innovative therapies. The company specializes in developing therapies for rare and life-threatening diseases that have no adequate treatment. Its business model is based on the discovery, development, and marketing of novel therapeutic products. It currently focuses on developing therapies in four different areas specializing in rare and life-threatening diseases: Hepatitis Delta (HDV), Pulmonary Arterial Hypertension (PAH), Lysosomal Storage Diseases (LSD), and COVID-19. The company has its own clinical development organization and proprietary technology called EigerOneTM. Eiger BioPharmaceuticals invests in research and development, holds patents and intellectual property, and has an international presence and partnerships to accelerate research efforts. Overall, its goal is to provide innovative solutions for patients with rare and life-threatening diseases.

What is the Eiger BioPharmaceuticals dividend?

Eiger BioPharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Eiger BioPharmaceuticals pay dividends?

The dividend cannot currently be calculated for Eiger BioPharmaceuticals or the company does not pay out a dividend.

What is the Eiger BioPharmaceuticals ISIN?

The ISIN of Eiger BioPharmaceuticals is US28249U1051.

What is the Eiger BioPharmaceuticals WKN?

The WKN of Eiger BioPharmaceuticals is A2AF9X.

What is the Eiger BioPharmaceuticals ticker?

The ticker of Eiger BioPharmaceuticals is EIGR.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

All fundamentals about Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.